The CCR5-agonist maraviroc reverses HIV latency, results from ex vivo studies and a randomized placebo controlled clinical trial

by J. Symons, S.F.L. van Lelyveld, W. de Spiegelaere, A.M.J. Wensing, J. Drylewicz, A.I.M. Hoepelman, P.U. Cameron, H. Lu, T. Mota, A.I. Dantanarayana, L. Vandekerckhove, S.R. Lewin, K. Tesselaar, M. Nijhuis
Published 2017-12-01

Post-mortem analysis of HIV-1 reservoir after allogeneic transplantation using stem cells

by M. Nijhuis, A. Bruns, M. Salgado, A.J. Stam, P.M. Ellerbroek, K. Tesselaar, P. van Ham, T.C.M. de Jong, G. Hutter, S.S. Zeerleder, J.T. van der Meer, L.L.A. Brosens, J. Martinez-Picado, J. Kuball, A.M.J. Wensing
Published 2015-12-01